Valuation: Cipher Pharmaceuticals Inc.

Market Cap 417M 297M 260M 240M 221M 28.63B 426M 2.87B 1.13B 14.02B 1.12B 1.09B 48.27B P/E 2026 *
13.4x
P/E 2027 * 11.9x
Enterprise Value 417M 297M 260M 240M 221M 28.63B 426M 2.87B 1.13B 14.02B 1.12B 1.09B 48.27B EV / Sales 2026 *
5.7x
EV / Sales 2027 * 4.93x
Free-Float
57.64%
Yield 2026 *
-
Yield 2027 * -
1 day+0.06%
1 week-4.26%
Current month-1.62%
1 month+0.43%
3 months-10.14%
6 months+6.98%
Current year+8.90%
1 week 16.17
Extreme 16.17
16.87
1 month 16
Extreme 16
17.8
Current year 14.2
Extreme 14.2
20.56
1 year 11.98
Extreme 11.98
20.56
3 years 3.35
Extreme 3.35
20.56
5 years 1.43
Extreme 1.43
20.56
10 years 0.38
Extreme 0.38
20.56
Manager TitleAgeSince
Chief Executive Officer - 2019-07-28
Director of Finance/CFO - 2024-08-09
Director of Finance/CFO - 2022-08-14
Director TitleAgeSince
Chairman - 2019-06-11
Director/Board Member 78 2023-06-20
Director/Board Member - 2023-06-20
Date Insider Type Main position Quantity % Market Cap.
6/24/26 Option

Chief Executive Officer

-2,500 0.0098%
6/24/26 Option

Director

-1,149 0.0045%
6/24/26 Option

Director

-2,500 0.0098%
Change 5-day change 1-year change 3-year change Capi.($)
+0.06%-4.26%+33.01%+337.33% 297M
+0.85%-0.80%+52.79%+159.97% 1,051B
+1.23%-1.53%+54.58%+59.41% 609B
+0.04%+2.58%+34.47%+84.84% 450B
+0.78%-0.71%+29.28%+23.25% 330B
+1.41%+0.58%+35.44%+40.53% 284B
-0.27%-1.87%+22.34%+19.92% 263B
-1.76%+2.37%-20.43%-38.01% 223B
-1.42%+0.80%+24.27%+57.85% 198B
-1.48%+3.43%+24.08%+70.06% 167B
Average -0.06%+0.06%+28.98%+81.51% 357.54B
Weighted average by Cap. +0.37%+0.02%+37.51%+78.78%

Financials

2026 *2027 *
Net sales 73.13M 52.2M 45.62M 42.09M 38.8M 5.03B 74.75M 503M 198M 2.46B 196M 192M 8.47B 84.52M 60.33M 52.72M 48.65M 44.84M 5.81B 86.4M 581M 229M 2.85B 227M 222M 9.8B
Net income 30.44M 21.73M 18.99M 17.52M 16.15M 2.09B 31.12M 209M 82.38M 1.02B 81.6M 79.81M 3.53B 36.1M 25.76M 22.52M 20.78M 19.15M 2.48B 36.9M 248M 97.67M 1.22B 96.76M 94.63M 4.18B
Net Debt - -
Logo Cipher Pharmaceuticals Inc.
Cipher Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products. The Company acquires products, manages the required clinical development and regulatory approval process, and markets those products either directly or indirectly in Canada, the United States and South America. The Company's product categories include dermatology, hospital acute care, out‑licensed, and specialty medicine. Its dermatology products include Actikerall, Epuris, Vaniqa and Natroba. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Absorica (isotretinoin) is an oral retinoid. Durela, its specialty medicine, is an opioid analgesic indicated for the management of moderate to moderately severe pain in adults who require continuous treatment for several days or more. Its pipeline products include Piclidenoson CF-101, MOB-015 and DTR-001.
Employees
5
Date Price Change Volume
26-07-17 $16.40 +0.06% 16,427
26-07-16 $16.39 -1.50% 18,583
26-07-15 $16.64 -0.72% 6,105
26-07-14 $16.76 -0.83% 13,529
26-07-13 $16.90 -1.34% 17,900
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
16.40CAD
Average target price
20.64CAD
Spread / Average Target
+25.84%

Quarterly revenue - Rate of surprise